447 related articles for article (PubMed ID: 34502160)
1. Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.
Le NQK; Kha QH; Nguyen VH; Chen YC; Cheng SJ; Chen CY
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502160
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
3. Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.
Shiri I; Amini M; Nazari M; Hajianfar G; Haddadi Avval A; Abdollahi H; Oveisi M; Arabi H; Rahmim A; Zaidi H
Comput Biol Med; 2022 Mar; 142():105230. PubMed ID: 35051856
[TBL] [Abstract][Full Text] [Related]
4. Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G; Barabino E; Fedeli A; Ficarra G; Coco S; Russo A; Adamo V; Buemi F; Zullo L; Dono M; De Luca G; Longo L; Dal Bello MG; Tagliamento M; Alama A; Cittadini G; Pronzato P; Genova C
Cancer Res; 2021 Feb; 81(3):724-731. PubMed ID: 33148663
[TBL] [Abstract][Full Text] [Related]
5. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
6. Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
Rizzo S; Raimondi S; de Jong EEC; van Elmpt W; De Piano F; Petrella F; Bagnardi V; Jochems A; Bellomi M; Dingemans AM; Lambin P
Eur J Radiol; 2019 Jan; 110():148-155. PubMed ID: 30599853
[TBL] [Abstract][Full Text] [Related]
7. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer.
Nair JKR; Saeed UA; McDougall CC; Sabri A; Kovacina B; Raidu BVS; Khokhar RA; Probst S; Hirsh V; Chankowsky J; Van Kempen LC; Taylor J
Can Assoc Radiol J; 2021 Feb; 72(1):109-119. PubMed ID: 32063026
[TBL] [Abstract][Full Text] [Related]
8. A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC.
Moreno S; Bonfante M; Zurek E; Cherezov D; Goldgof D; Hall L; Schabath M
Tomography; 2021 Apr; 7(2):154-168. PubMed ID: 33946756
[TBL] [Abstract][Full Text] [Related]
9. Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.
Gu Q; Feng Z; Liang Q; Li M; Deng J; Ma M; Wang W; Liu J; Liu P; Rong P
Eur J Radiol; 2019 Sep; 118():32-37. PubMed ID: 31439255
[TBL] [Abstract][Full Text] [Related]
10. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
11. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
12. Efficient 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based machine learning model for predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Ruan D; Fang J; Teng X
Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):70-83. PubMed ID: 35420272
[TBL] [Abstract][Full Text] [Related]
13. Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer.
Li S; Ding C; Zhang H; Song J; Wu L
Med Phys; 2019 Oct; 46(10):4545-4552. PubMed ID: 31376283
[TBL] [Abstract][Full Text] [Related]
14. Hybrid deep multi-task learning radiomics approach for predicting EGFR mutation status of non-small cell lung cancer in CT images.
Gong J; Fu F; Ma X; Wang T; Ma X; You C; Zhang Y; Peng W; Chen H; Gu Y
Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37972417
[No Abstract] [Full Text] [Related]
15. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
16. Deep learning-radiomics integrated noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients.
Kim S; Lim JH; Kim CH; Roh J; You S; Choi JS; Lim JH; Kim L; Chang JW; Park D; Lee MW; Kim S; Heo J
Sci Rep; 2024 Jan; 14(1):922. PubMed ID: 38195717
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
19. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
